MEK inhibitor

DRUG CLASS:

MEK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1	cetuximab + binimetinib + encorafenib Sensitive: A1 - Approval cetuximab + binimetinib + encorafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	trametinib Resistant: A1 - Approval trametinib Resistant : A1	trametinib Resistant: A1 - Approval trametinib Resistant : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1	trametinib Sensitive: A1 - Approval trametinib Sensitive : A1
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600	Non Small Cell Lung Cancer	BRAF V600	Non Small Cell Lung Cancer	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600K	Melanoma	BRAF V600K	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Melanoma	BRAF V600E	Melanoma	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Glioma	BRAF V600E	Glioma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Non Small Cell Lung Cancer	BRAF V600E	Non Small Cell Lung Cancer	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1	binimetinib + encorafenib Sensitive: A1 - Approval binimetinib + encorafenib Sensitive : A1
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	trametinib Resistant: A2 - Guideline trametinib Resistant : A2	trametinib Resistant: A2 - Guideline trametinib Resistant : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
BRAF V600E	Neuroendocrine Tumor	BRAF V600E	Neuroendocrine Tumor	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2	binimetinib + encorafenib Sensitive: A2 - Guideline binimetinib + encorafenib Sensitive : A2
BRAF V600	Melanoma	BRAF V600	Melanoma	BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline BRAF inhibitor + MEK inhibitor Sensitive : A2	BRAF inhibitor + MEK inhibitor Sensitive: A2 - Guideline BRAF inhibitor + MEK inhibitor Sensitive : A2
BRAF V600E	Biliary Tract Cancer	BRAF V600E	Biliary Tract Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
BRAF V600E	Cholangiocarcinoma	BRAF V600E	Cholangiocarcinoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2

MEK inhibitor

MEK inhibitor

Associations(670)

Associations
(670)